Although recent results in clinical trials using the tyrosine kinase receptor inhibitor imatinib mesylate, which targets PDGFR and c-Kit, have not been encouraging (Mathy, 2005; Porta, 2007), it is to be hoped that the common effort of medical and research disciplines will in the future allow us to achieve more success in treating this highly lethal tumor. This evidence concerns the gene NTRK1 and neoplasm.